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A B S T R A C T
The ﬁelds of toxicology and chemical risk assessment seek to reduce, and eventually replace, the use of animals
for the prediction of toxicity in humans. In this context, physiologically based kinetic (PBK) modelling based on
in vitro and in silico kinetic data has the potential to a play signiﬁcant role in reducing animal testing, by
providing a methodology capable of incorporating in vitro human data to facilitate the development of in vitro to
in vivo extrapolation of hazard information. In the present article, we discuss the challenges in: 1) applying PBK
modelling to support regulatory decision making under the toxicology and risk-assessment paradigm shift to-
wards animal replacement; 2) constructing PBK models without in vivo animal kinetic data, while relying solely
on in vitro or in silico methods for model parameterization; and 3) assessing the validity and credibility of PBK
models built largely using non-animal data. The strengths, uncertainties, and limitations of PBK models devel-
oped using in vitro or in silico data are discussed in an eﬀort to establish a higher degree of conﬁdence in the
application of such models in a regulatory context. The article summarises the outcome of an expert workshop
hosted by the European Commission Joint Research Centre (EC-JRC) – European Union Reference Laboratory for
Alternatives to Animal Testing (EURL ECVAM), on “Physiologically-Based Kinetic modelling in risk assessment –
reaching a whole new level in regulatory decision-making” held in Ispra, Italy, in November 2016, along with
results from an international survey conducted in 2017 and recently reported activities occurring within the PBK
modelling ﬁeld. The discussions presented herein highlight the potential applications of next generation (NG)-
PBK modelling, based on new data streams.
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1. Introduction
Modelling and simulation based approaches are gradually gaining
interest as critical tools for safety and risk assessment of a variety of
compounds including drugs, chemicals, consumer products, and food
ingredients. These modelling approaches are recognised for the crucial
role they play in, for example, predicting the biokinetics of drugs and
chemicals in the organism without the need to conduct in vivo experi-
ments. For more than 40 years, physiologically-based kinetic (PBK)
models have been used to simulate biokinetics [2,41,28,11]. In PBK
models, the body is represented as a series of interconnected com-
partments linked via blood ﬂow, as depicted in the schematic below
(Fig. 1a), to simulate concentration-time curves in target organs or their
surrogates, such as in blood (Fig. 1b). PBK models use diﬀerential
equations to describe the absorption, distribution, metabolism, and
elimination (ADME) processes that govern the fate and transport of the
chemical among these interconnected compartments. Proper use of PBK
models helps to reduce uncertainties and to identify data gaps inherent
in hazard characterisation approaches that rely upon default extra-
polation factors (e.g., a multiplication factor of 10 for inter-species
extrapolation) to derive health-based guidance values from animal
toxicity studies. PBK models provide a sound scientiﬁc basis to extra-
polate across species, routes of exposure, and exposure scenarios, based
on physiology and (physico-)chemical properties [32,6]. As PBK models
can be developed for speciﬁc individuals within the human population,
they provide a means for quantifying inter-individual diﬀerences in
kinetics, allowing for the determination of extrapolation factors across
age groups or across populations of varying susceptibilities. With this
information, safe chemical intake levels can be derived for individuals
and populations. Most recently, PBK models have helped to facilitate
quantitative in vitro to in vivo extrapolation (QIVIVE) approaches
[70–73,72,67,35], enabling the use of in vitro toxicity data for the set-
ting of safe intake levels. QIVIVE is an essential process in linking an in
vitro measured biological (adverse) readout to a potential in vivo out-
come [23]. QIVIVE provides a means of considering exposure and do-
simetry, and enables the use of in vitro toxicity data for risk-based as-
sessments beyond hazard-based assessments [5]. Once an in vitro
concentration-response has been generated, the benchmark dose ap-
proach can be applied to the predicted dose-response data, to obtain an
in vitro-based point of departure (PoD) or Reference Point (RfP)
[34,35].
1.1. Nomenclature
“Physiologically based pharmacokinetic” (PBPK) model is the most
widely used term and was developed by the pharmaceutical ﬁeld to
simulate the kinetics of drugs. Despite the popular use of the term,
“PBPK” is not entirely correct in the context of general chemical risk
assessment. Another term preferred in the European Union (EU) and
related to chemical risk assessment is “PBTK”, where TK is the ab-
breviation for “toxicokinetics”. However, this term is not entirely ap-
propriate either [17]. Rather, a more general nomenclature, such as
physiologically based biokinetic (PBBK) or the aforementioned PBK,
might be seen as more appropriate. Regardless of the terminology used,
PBK, PBPK, PBBK and PBTK can all be considered synonyms, and so
throughout this document we will consistently use the more general
terms of PBK model or PBK modelling. It is noted that the ever-in-
creasing advancements in in vitro and in silicomethodologies in the ﬁeld
of toxicology can be used in combination with PBK models to support
regulatory decisions on the use of chemical substances. In the present
manuscript the term next generation PBK (NG-PBK) model will be used
to name these models. This term, NG-PBK, refers to PBK models that are
developed without the provision of newly produced (i.e., without an-
imal sacriﬁce) animal TK data for parametrisation and validation of
those models, but rather through supporting in vitro, in silico, -omics,
and micro-scale applications. NG-PBK models representing the human
body should be parameterized and validated using in vitro, in silico,
-omics data, micro-scale systems, and human in vivo data, when avail-
able. This stands also for PBK models built to represent animals (e.g.
livestock, ﬁsh, bees), which should be parameterized and validated
using in vitro, in silico, -omics, micro-scale systems and historical or
(bio)-monitoring animal data of the species of interest, to avoid the
need for animal sacriﬁce.
1.2. Milestones in the history of PBK modelling
The principles behind PBK modelling were ﬁrst reported in 1937 by
Teorell, in a publication entitled “Kinetics of distribution of substances
administered to the body” [58]. Although Teorell’s work was the ﬁrst
attempt to describe the body as a series of equations, the complexity of
the mathematics, lack of data, and lack of computing power rendered
his concepts incomplete until the 1960s. Between the 1960s and 1970s,
several PBK models were developed for pharmaceutical drugs to target
cancers [7,8]. These publications paved the way for more than 2000
articles written on the topic of PB(P/T)K modelling within the last forty
years (Fig. 2a). Over the past decade, there has been an increase in the
development of PBK models for use in a variety of scientiﬁc ﬁelds, such
Fig. 1. (a) Schematic representation of a physiologically based kinetic (PBK)
model, (b) with an example of a typical PBK model-output (time-dependent
chemical concentration in blood).
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as pharmacology, forensic sciences, and chemical risk assessment
(Fig. 2b), although such an increase was not seen for toxicology and
veterinary medicine. Many risk assessors remain reluctant to apply
these models within their work [43,49,50], as PBK models are not often
included in current hazard characterization and risk assessment pro-
tocols. In addition, some regulatory agencies may often have limited
experience in using PBK models, and the complexity associated with the
evaluation of model performance has also contributed to this re-
luctance.
Over the past 20 years, several workshops have been held to pro-
mote the applicability of PBK models in the academic, industrial, and
regulatory sectors. For example, a 1995 European Centre for the
Validation of Alternative Methods (ECVAM) workshop discussing the
use of biokinetic and in vitro methods resulted in 15 recommendations
that were submitted to support and guide future work in the PBK
modelling ﬁeld [9]. This workshop was followed by many others to
better deﬁne the potential role of PBK modelling in science and risk
assessment following a Three R (replacement, reduction and reﬁne-
ment) strategy [10]. In the same year, a workshop to address un-
certainty and variability analysis in PBK modeling was held [4]. Loizou
et al. [32] reported the need for clear descriptions of good modelling
practices (GMP) for: 1) model development; 2) model characterisation;
3) model documentation; and 4) model evaluation. A subsequent
thematic workshop aimed to critically appraise PBK modelling software
platforms and to provide a more detailed state-of-the-art overview of
non-animal based PBK parameterisation tools [6]. A CEN (European
Committee for Standardization) workshop in 2014 strived for agree-
ment upon the minimum requirements for the amount and type of in-
formation to be provided for exposure models, such as PBK models,
along with documentation and guidelines for the structure and re-
porting of such information. The resulting CEN workshop agreement
was expected to provide a more rigorous means of describing exposure
models and to aid users in better understanding them [13,1]. The fol-
lowing year, a workshop assessed the state of knowledge in the appli-
cation of PBK models in regulatory decision-making, in addition to
sharing and discussing best practices in the use of PBK modelling to
inform dose selection in speciﬁc patient populations [61]. In 2017, a
workshop organized by the National Centre for the Replacement, Re-
ﬁnement, and Reduction of Animals in Research (NC3Rs) encouraged
experts in exposure science to consider the role of PBK models in the
extrapolation of external exposure data to internal concentrations to
promote the application of non-animal data in eﬃcacy and safety
testing (Burden et al., 2017; https://www.nc3rs.org.uk/applying-
exposure-science-increase-utility-non-animal-data-eﬃcacy-and-safety-
testing). A Lorentz Center workshop entitled “Non-animal Methods for
Toxicokinetics: Meeting New Paradigms in Toxicology” was held at the
Fig. 2. (a) Number of papers published per year within the last 60 years. The search was conducted using the online repository PubMed on the 7th of March 2018,
with key words string including “PBPK OR PBBK OR PBTK OR PBK”. (b) The number of papers (Fig. 2 A) published with key words string including “PBPK OR PBBK
OR PBTK OR PBK” were normalized to the following terms: Toxicology; Pharmacology; Chemical Safety OR Risk assessment; Forensic Sciences and Veterinary.
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end of 2017 and emphasized the role of PBK models (https://www.
lorentzcenter.nl/lc/web/2017/943/info.php3?wsid=943&ve-
nue=Oort; https://www.lorentzcenter.nl/lc/web/2017/943/report.
pdf). The ﬁrst European Partnership for Alternative Approaches to
Animal Testing (EPAA) partners’ forum, held at the end of 2017, aimed
to provide an overview on toxicokinetics and read-across with insight
into the role of PBK models [30].
1.3. Framing the problem
The EURL ECVAM Strategy on Toxicokinetics1, as published in
2015, outlines opportunities for generating and making better use of TK
data. The central feature of the strategy focuses on the use of PBK
modelling to integrate data from in vitro and in silico methods for pre-
diction of human whole-body biokinetic behavior, and enables QIVIVE
to obtain safety guidance values expressed as external doses [5]. In the
past, in vivo tissue/blood concentration-time data were a prerequisite
for calibrating and evaluating the predictive capability of a PBK model
[6]. The common practice was to start with an animal PBK model,
calibrating it with animal in vivo data, and then re-parameterizing it
based on in vitro biotransformation measurements or allometric scaling
to develop a human PBK model. As the ﬁeld of risk assessment evolves
towards the goal of reducing, and eventually replacing, the use of an-
imals for predicting human toxicity, PBK model development has seen a
shift towards increased use of non-animal data for parameterization,
along with increased use of the models for IVIVE. Eﬀorts in this area
should be directed towards developing standards that will increase the
acceptance of in vitromethods for characterizing human-relevant ADME
properties. To enhance the acceptance of PBK models at an interna-
tional level, good modelling practice is required to guide the use of the
in vitro and in silico methodologies in developing PBK models. As the
ﬁrst step, to initiate a dialogue on such a topic, the European Com-
mission’s Joint Research Centre (JRC), EURL ECVAM, hosted a work-
shop on “Physiologically-Based Kinetic modelling in risk assessment –
reaching a whole new level in regulatory decision-making” (Ispra, Italy,
November 16–17, 2016). The workshop participants discussed chal-
lenges in: 1) applying NG-PBK modelling to support regulatory decision
making; 2) constructing PBK models for safety assessment without an-
imal in vivo data, relying solely on in vitro or in silico methods; and 3
assessing the validity of PBK models that rely only upon non-animal
data. A portion of this current article summarizes the outcome of the
workshop; detailed information on the workshop outcomes can be
found in the workshop report [42].
In addition to the EURL ECVAM workshop, an international survey
was conducted in 2017 to understand the applications of PBK modelling
in the broader scientiﬁc and regulatory communities. An aggregate
summary, including analysis of the results, has been published [43],
while results presented per individual country are available online at
http://apps.klimeto.com/pbk/. The survey provides insight into the
current state of knowledge throughout the PBK modelling and user
community, as well as a cursory volunteer contact list of modellers
available for peer reviewing models. The main ﬁndings of the survey
showed that though continuous expansion of the modelling community
has allowed PBK models to gain ground for use in various scientiﬁc and
regulatory risk assessment applications, this remains a slow process,
due to a lack of guidance, data, and expertise, which continue to limit
widespread acceptance of those models in such applications [43]. Here,
we also discuss recently reported activities in the ﬁeld, (subsequent to
the 2016 EURL ECVAM workshop) that demonstrate both ongoing de-
velopments and the continued hesitancy within public health agencies
to apply PBK modelling in their decisions. In addition, we will
introduce as a new challenge the integration of NG-PBK modelling with
toxicodynamic endpoints, as this will be essential for implementation of
NG-PBK models.
2. Salient Features: Applying NG-PBK modelling to support
regulatory decision making
As concluded from the 2017 survey [43], training, guidance, and
dialogue are three main factors that will facilitate the successful ac-
ceptance of NG-PBK modelling in regulatory decision-making.
2.1. Dialogue and communication
While training and guidance are both essential, their maximum
beneﬁts cannot be achieved without frequent dialogue between reg-
ulators, modellers, and model proponents (chemical registrants). Such
frequent dialogue not only allows the proposers to better understand
the needs of the regulators, but also allows the regulators to provide
modellers with feedback throughout the development, evaluation, and
application processes. For example, risk assessors present at the 2016
EURL ECVAM workshop indicated that they prefer to use the simplest
model possible, as ﬁnding suﬃcient input data is rather challenging,
but would be willing to use more complex models if necessity dictates
and suﬃcient input data are available. Thus, dialogue can help reg-
ulators to convey their needs for speciﬁc training and for model fea-
tures, and help proponents to understand the criteria necessary for
regulatory acceptance. Conversely, the regulators can learn what is
technically or scientiﬁcally feasible and what is not. As such dialogue
may prove to be time-consuming, establishing a harmonized template
for model construction and evaluation would facilitate the process. The
template should be ﬂexible enough for any regulatory agency or
country to use, and would ideally incorporate an agreed-upon ontology.
To eﬃciently develop a PBK model to support regulatory risk assess-
ment, modellers and end users (proponents and regulators) need to
clearly deﬁne their goals of model use and related model requirements
at an early stage. For example, if a read-across approach is likely to be
applied by the end users, biokinetic data for a pre-determined set of
relevant chemicals (target and source chemicals) will constitute im-
portant supporting material and should be included in the submission
package. In situations where safety assessment is conducted for a new
chemical on the market, the following criteria may be used to facilitate
regulatory acceptance of a PBK model for this substance: 1) the model
should be transparent, with a usable code; 2) model uncertainty should
consider biological plausibility, and be clearly described and quantiﬁed
when possible; 3) uncertainty in exposure scenarios should be char-
acterised, because this uncertainty will propagate to PBK model results;
4) user-friendly platforms should be used where possible; 5) the model
should be ﬁt-for-purpose with no unnecessary additional complexity,
and with all required parameters measurable; and 6) the model should
consider suﬃcient coverage of chemical space, to allow for read-across
approaches if desired. In cases where the model performance needs to
be evaluated using human in vivo data, regulators may consider using
data that are generated from human trials, such as micro-dosing. It
should be emphasized that clinical studies would only be conducted
once the safety of the chemical has been established and the clinical
investigation represents de minimis risk to the subjects.
2.2. Training
Within the current climate of desire to reduce, reﬁne, and replace
animal testing through ongoing scientiﬁc and technological advance-
ments, it would be beneﬁcial to risk assessors/managers and other
workers in safety assessment to be kept abreast of the development of
NG-PBK models. In order to achieve this goal, information on a number
of novel emerging technologies, in addition to PBK modelling, should
be made more accessible. These include -omics, organ- on-a -chip, high-
1 https://ec.europa.eu/jrc/en/publication/eur-scientiﬁc-and-technical-
research-reports/eurl-ecvam-strategy achieving-3rs-impact-assessment-tox-
icokinetics-and-systemic-toxicity?search
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throughput screening methods, read-across, Adverse Outcome
Pathways (AOPs), and IVIVE. Additionally, it would be helpful if gui-
dance were available indicating how these diﬀerent approaches are
integrated in support of chemical safety assessment. On the other hand,
it is not necessary for risk assessors/managers, etc. to have detailed
knowledge related to all the diverse aspects of PBK modelling; rather, it
may be suﬃcient to provide tailored training that focuses only on the
speciﬁc needs of each regulatory sector and, where applicable, cross-
sector needs. For example, some risk assessors may need or wish to run
a model, and so they would require knowledge of the relevant software
and expertise to review and run model codes. Other risk assessors may
rely on a model peer review system to check the implementation and
reliability of new model codes, and in this case, may only require suf-
ﬁcient knowledge to allow for interpretation of the data and to enable
modelling predictions to be put in context. One option is for risk as-
sessors to assemble technical committees that consist of members pos-
sessing a range of expertise, to review the model code and interpret
model results. The training content/format should also be tailored to
achieve maximum eﬀectiveness in understanding the application of
models. In addition to the traditional classroom setting, training for-
mats could include webinars, ad hoc short courses, and more reﬁned or
specialised graduate-level courses. Further, online training could po-
tentially generate a larger audience that would also allow the modelling
and user community to continue to expand. Finally, since risk assessors
generally place higher conﬁdence in in vivo data, there is a need to
make courses on alternative in vitro and in silico methods more acces-
sible, to provide a path forward to acceptance of these NG-PBK model
applications in regulatory decision making.
2.3. Guidance
While training is essential, establishing guidance and GMP on PBK
model applications intended for regulatory purposes is also critical
[32]. The GMP should include clear documentation on how to report a
model’s scope and purposes, details of model development and eva-
luation, interpretation of results, and applications of the model in risk
assessment [32]. It is recommended that the individual(s) or commu-
nity network(s) responsible for each speciﬁc step in the development,
evaluation, and application process be clearly identiﬁed, to increase
transparency and allow end users to identify where targeted training
may be required, if necessary, for a speciﬁc topic. The context in which
the model is to be used, and thus the scope of the model development or
amendment(s), should be clearly documented. This is especially im-
portant to avoid misuse of a reliable model, such as when results of the
simulations are applied for the wrong purpose or when the model is
applied outside of its applicability domain.
The WHO-IPCS published, in 2010, a guidance document on the
characterisation and application of PBK models in risk assessment [68].
Nevertheless, no comprehensive guidance documentation is currently
available for reporting and evaluating NG-PBK models without use of
animal in vivo TK data, or for interpreting and applying outputs from
these models for human safety assessment. Recently, several eﬀorts
have been made to produce such documentation. For example, the
Scientiﬁc Committee for Consumer Safety (SCCS) considers all available
scientiﬁc data in their safety evaluation of cosmetic substances, in-
cluding data generated from PBK modelling. In the most recent Notes of
Guidance for the Testing of Cosmetic Ingredients and Their Safety
Evaluation (SCCS/1564/15)2, the SCCS deﬁnes the conditions for the
use of PBK models submitted for risk assessment purposes. PBK mod-
elling has already been accepted as a tool for risk assessment or for use
as supporting information in some of the chemical-speciﬁc dossiers
evaluated by the SCCS, EFSA, and US-EPA. The SCCS document could
act as a starting point or as a template for a new general guidance
document. Additionally, the new reporting guidelines from the US Food
and Drug Administration (FDA) and European Medicine Agency (EMA)
[60,20], on harmonization of reporting and on qualiﬁcation of PBK
modelling and simulation, can also apply to NG-PBK models. To extend
this concept, a working group at the Organisation for Economic Co-
operation and Development (OECD), comprised of more than 45 sci-
entists from diﬀerent areas of scientiﬁc expertise, are drafting a gui-
dance document for characterizing, validating, and reporting un-
certainties in NG-PBK model applications.
3. Salient Features: Constructing PBK models for safety
assessment without animal in vivo data
PBK models are built using three sets of parameters: i) physiological
and anatomical parameters, with representative reference parameters
taken from the species under study (animal or human); ii) biokinetic/
ADME properties, which can be gathered using in vitro methods or by
ﬁtting the model to an in vivo data set; and iii) physico-chemical
parameters, which are experimentally derived or obtained using in silico
approaches such as quantitative activity relationship (QSAR) models
[51]. For GMP, the PBK model construction should consider the com-
pound exposure situation/dosing strategy to be simulated (problem
formulation). The exposure descriptions should include route of ad-
ministration, timeframe of the simulation (i.e. exposure duration), and
exposure frequency. In the cases of complex models that include inter-
individual variability among some physiological values, the number of
individuals that should be incorporated into the simulation for suﬃ-
cient statistical power analysis should also be considered.
In the case of NG-PBK models, assuming there is no possibility of
generating in vivo animal data for the model calibration, there are two
key pre-requisites to build the model:
• Availability of in vitro and in silico alternatives to generate ADME
properties (including prediction of metabolism) of suﬃcient quality
• Availability and accessibility of modelling platforms.
3.1. Availability of in vitro and in silico data for ADME properties
Without in vivo data, the values of parameters in a PBK model will
need to be derived from the results of in silico or in vitro experiments.
Clearly, the accuracy of PBK models will be heavily reliant upon the
quality of the model parameters, which often are not only tissue de-
pendent but also chemical dependent.
As it is useful to determine the minimum requirements for PBK
models (with respect to data-poor and data-rich chemicals), a decision
tree indicating requirements for diﬀerent scenarios is presented here
(Fig. 3). The most minimalistic model type, one-compartment models,
parameterised with only protein binding and clearance data, have been
developed and used to support chemical screening and prioritization
[52,64,65,66,59,71,62]. Depending on the exposure route, a compart-
ment representing the skin, intestine, or lung may need to be included
in a model. If a compound is highly lipophilic, a fat compartment is
required, and it may also be necessary for the model to describe uptake
into the lymphatic system. Finally, depending on the hazard data
available, additional compartments and biological processes may need
to be added to the PBK model. Throughout development of the model,
as more speciﬁc information is obtained on the chemical’s properties
and mode of action (MoA), conﬁdence is increased in the applicability
of the models. A good strategy would be to begin with a generic model
structure, then move to more speciﬁc models once knowledge is gained
that indicates a unique biokinetic behavior of the compound in ques-
tion. In using a simple model, it is possible that a key kinetic pathway
speciﬁc to a given target chemical will not be taken into consideration.
To address this issue, a database of all known ADME/TK processes, such
as cell uptake (capturing the role of transporters), metabolism, and
2 http://ec.europa.eu/health/scientiﬁc_committees/consumer_safety/docs/
sccs_o_190.pdf
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eﬄux, could be developed to help modellers identify which processes
may need to be included for a speciﬁc chemical / purpose.
Membrane transporters inﬂuence the ADME processes of various
endogenous and exogenous compounds [25,54]. In recent decades, the
pharmaceutical ﬁeld has placed considerable eﬀort into the study of
transporters aﬀecting drug disposition, therapeutic eﬃcacy, and ad-
verse outcomes, but little is known in regards to transporter eﬀects on
environmental chemicals [15]. Transporters can play a signiﬁcant role
in chemical distribution. As such, integration of membrane transporter-
based experimental data during parameterization of several types of
computational models (e.g., QSAR, pharmacophore, and PBK models),
through use of platforms like SimCyp, PKSim, or GastroPlus, will enable
better understanding of chemical/drug disposition [15].
Protein binding in plasma inﬂuences the partitioning of endogenous
and exogenous compounds from the blood into the tissues. The plasma
protein binding property is, among other things, related to lipophilicity,
as binding becomes greater with more lipophilic chemicals, thus se-
questering such chemicals in blood and limiting the systemic avail-
ability and distribution of unbound fraction of the chemical. A common
and widely used method for estimating plasma protein binding in vitro
is the rapid equilibrium method, which involves measurement of che-
mical transport across a dialysis membrane with a high surface area-to-
volume ration within a Teﬂon-lined plate well [63].
Metabolism is an important feature to consider in a model, espe-
cially when a metabolite is assumed or known to be the toxic moiety.
Both in vitro and in silico methods can be informative in providing
predictions for metabolism and clearance. Kirchmair et al [24] re-
viewed software for predicting a range of features associated with
metabolism (e.g. identiﬁcation of labile moieties, enzyme interactions
and metabolite prediction). The focus of these in silico tools is mainly
the estimation of the qualitative nature of the metabolites (i.e., which
metabolites are formed based on the parent compound’s molecular
structure) and seldom allows for estimation of rate constants. A
common criticism of software for predicting metabolites is the tendency
for over-prediction: theoretically possible metabolites are not diﬀer-
entiated from those that occur experimentally. Some software platforms
have attempted to address this issue through inclusion of ﬁltering rules.
For example, in order to reduce over-prediction within the Meteor
Nexus software (Lhasa Ltd, Leeds), Marchant et al [37] describe a
process whereby k-nearest neighbor analysis is combined with expert
knowledge of biotransformation to reduce the over-prediction of me-
tabolites. Such in silico models do not predict eﬄux of metabolites.
In vitro data for metabolism may be generated using tissue slices,
organ (e.g., liver) homogenates, cell lines, spheroids, or (sub)cellular
fractions (such as microsomes, baculosomes, S9, and cytosol), where
metabolism is measured as loss of the parent compound or production
of metabolite(s). It should be noted that if metabolism occurs very
slowly, it may not be detected in a short-term in vitro assay. If a che-
mical is known to be predominantly excreted unchanged in urine, then
metabolism is less relevant to the model. However, if metabolism of a
parent compound is thought to be metabolized to undergo biliary ex-
cretion or to be excreted via the bile, then a model including such
Fig. 3. An example of a schematic decision tree to decide what tier of PBK model to apply when encountering data-poor or data-rich chemicals during model
parameterization and based on problem formulation.
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elimination pathways is necessary, ﬁrst by determining which pathways
of elimination are most relevant to the target chemical. In silico and in
vitro models have also been developed for predicting diﬀerent processes
involved in elimination. These include in silico models for total clear-
ance [77] and metabolism [47] and in vitro models for biliary excretion
[22]. However, more work is required to develop models for elimina-
tion, and the applicability domain for existing models should be care-
fully considered before application to a wider range of chemicals. A
current limitation is that there are no (OECD) guideline(s) addressing in
vitro methods to determine kinetic parameters, except for the guideline
on Skin Absorption (OECD TG 428). In the absence of standardised
methods for generating in vitro parameters to calibrate PBK models, it is
important that in vitro metabolism data or data regarding transporters
are produced according to the new OECD good in vitro method practice
(GIVIMP)3. The GIVIMP document is meant to serve as technical gui-
dance on generating and applying quality data through good scientiﬁc
and quality practices, to support the regulatory human safety assess-
ment of chemicals using in vitro methods.
Bessems et al. [6] provides a general overview of the currently
available in vitro and in silico methods for characterizing human ADME
and the gaps and challenges faced. Mostrag-Szlichtyng et al [40] pro-
vide an extensive review speciﬁcally of in silico tools (i.e., QSAR models
and software) for prediction of ADME properties that are relevant to
PBK model building. More recently, Patel et al [44] have collated and
assessed the quality of over 80 models for 31 absorption-, distribution-,
and excretion-related endpoints [44].
Finally, toxicodynamic data derived from in vitro toxicity tests are
typically based on nominal concentrations of the substances, which
may contain signiﬁcant errors due to the loss of biological, physical,
and toxicological chemical processes in such tests. An in vitro biokinetic
study plays a signiﬁcant role in translating a nominal concentration
used in in vitro systems to the actual level of cell exposure producing the
eﬀect. Several methodologies can be applied to address such a re-
lationship, such as in vitro fate and transport mass balance models re-
cently developed by several research teams [26,27,3,21,73].
3.2. Availability of modelling platforms
Currently, several open source modelling platforms, such as
IndusChemFAte (Ceﬁc LRI, http://ceﬁc-lri.org/toolbox/
induschemfate/), High-Throughput Toxicokinetics (httk)-r package
([74] https://cran.r-project.org/web/packages/httk/index.html),
MEGEN-RVis ([33]; https://megen.useconnect.co.uk/), PLETHEM
(http://www.scitovation.com/plethem.html), MERLIN-EXPO ([14,55];
https://merlin-expo.eu/), and PK-Sim (www.systems-biology.com),
and license-based platforms such as GastroPlus (www.simulations-plus.
com) and SimCyp (https://www.certara.com), are available to in-
dividuals possessing varying degrees of expertise in PBK modeling.
These platforms provide diﬀerent computational tools that allow non-
programmers to develop and run model simulations with varying op-
tions to gain a better understanding of model behavior, which is es-
sential for interpretation of model output. The PBK models run from
these platforms can be parameterised using in vitro or in silico data.
However, programmers or users with modeling skills can also use R,
MATLAB, and Berkeley Madonna software to develop customised PBK
models, and to support the generation of innovative modeling compo-
nents, which might otherwise not be generated through use of the
more-structured commercial platforms.
A concern for the use of open source modelling platforms, as com-
pared to use of their proprietary counterparts, is the lack of sustainable
resources and funding that are needed for further development and
maintenance of those platforms. While most of these platforms are
initiated by a research grant, upon completion of the project, the de-
velopers are often unable to ﬁnd other funding sources to maintain
them. In order for a modelling platform to remain sustainable, it is
essential to maintain access to the model’s equations, so that these can
be easily coded later. Sustainability also depends on the ability of model
updates to be communicated to end-users. Establishment of an open
source library as a repository for all available model information, in-
cluding a peer review process, is strongly recommended.
3.3. Integrating NG-PBK modelling with toxicodynamic endpoints
There is high value in the use of PBK models to predict internal
target tissue doses for risk assessment applications, based on the as-
sumption that a similar tissue response arises from an equivalent target
tissue dose, rather than the external dose, across diﬀerent exposure
conditions. In addition, toxicodynamic processes that are interpreted in
a high-throughput context from in vitro dose–response data can be in-
tegrated with PBK models, to link external exposure concentrations to
target tissue doses to adverse endpoints. Such integration allows for
support of several risk assessment extrapolations, such as QIVIVE and
reverse dosimetry approaches. Examples of PBK/TD models are re-
ported in table 3 of Punt et al. [75]. However, the application of PBK/
TD models in risk assessment requires proper evaluation of model
purpose, model assumptions and structure, mathematical representa-
tion, parameter estimation, computer implementation, and predictive
capacity.
The topic of model evaluation will be captured in the next chapter.
4. Salient Features: Model evaluation- assessing the validity of
PBK models that rely only upon non-animal data
A question that often arises is “How can we trust a PBK model pre-
diction if there are no in vivo data to evaluate the simulation; how can the
model gain credibility then?”
The following approaches could be applied and are described in
further detail below: 1) read-across; 2) micro-scale systems; 3) prag-
matic conservative scenario approach; 4) “credibility matrix”; 5) the
reliability of dose metric predictions provided with uncertainty and
sensitivity analyses (WHO 2010); and 6) population characteristics and
virtual population libraries.
4.1. Read-across
For those cases in which in vivo data exist for one chemical, a read-
across approach4 may be applied to parameterize models for other
chemicals [76]. For example, if a valid PBK model exists for chemical A
(source chemical), and chemical B (target chemical) lacks any in vivo
data and has been shown to be similar in structure to chemical A, then
the same parameterised PBK model structure/code and in vivo data for
chemical A can be used for chemical B. This read-across approach has
been demonstrated by case studies applying the PBK Knowledgebase
developed by Lu et al. [36]. Alternatively, if parameterisation of the
PBK model using available in vitro or in silico data for chemical B is
possible, predictions can be compared to output from the model for
chemical A based on in vivo data, in order to evaluate the PBK model for
chemical B. When using such a model based on similarity between
diﬀerent chemicals, the inﬂuence of chemical-speciﬁc properties med-
iating ADME behaviour (e.g., log P, speciﬁc functional groups) should
3 http://www.oecd.org/env/ehs/testing/OECD_Draft_GIVIMP_in_Human_
Safety_Assessment.pdf
4 Quotation: “The underlining philosophy of read-across is that substances
which are similar in chemical structure will have similar properties and
thereby, have similar toxicokinetics and toxicodynamics. Experimental derived
toxicological proprieties from one substance, often referred to as source che-
mical, can be read across to ﬁll the data gap for a second substance, the target
chemical, which has a similar molecular structure but is lacking data” [76].
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be carefully considered.
4.2. Micro-scale systems
Microscale systems, such as human-on-a-chip technology, could
potentially be applied to measure and predict kinetics and whole body
response to substances [56], thus aiding in evaluation and increased
conﬁdence in NG-PBK models. However, the limitations of these novel
microscale systems should be carefully considered. For example, ﬂow
rates from model systems are often not scaled down in a similar manner
as tissue volumes, thus rendering interpretation of the data diﬃcult for
PBK model applications.
4.3. Pragmatic conservative scenario approach
When in vivo data are lacking for model evaluation, a pragmatic
conservative scenario could be followed in order to derive the most
conservative estimate for risk assessment. For NG-PBK modeling, such
an approach needs to be designed in such a way that the structure and
input of the model is likely to lead to an overestimation of the internal
concentration. This can be achieved by including uncertainty factors in
the input parameters of the model. A worst-case estimate for absorption
can for example be set to 100%. Other input parameters, such as me-
tabolic clearance can be set to a value that is a certain extent lower than
that measured for in vitro rates. To deﬁne the conservative boundaries
around each input parameter, the uncertainties of each in vitro or in
silico input method need to be identiﬁed.
4.4. Credibility matrix
There is a need to develop a framework for supporting the cred-
ibility of PBK models in support of risk assessment applications. As a
ﬁrst requirement for credibility, PBK models should be biologically
plausible. Often, modellers or mathematicians exclude a number of
biologically-relevant processes because these processes are considered
to have no bearing on the model results and because models should be
kept as simple as possible and created following the required purpose/
problem formulation. However, such assumptions must always be dis-
cussed and agreed upon with biologists and toxicologists, to prevent the
omission of critical biological and toxicological steps or key events.
Good documentation of model assumptions is critical for modelers to
demonstrate the validity of their models to reviewers and users, and
visualization is a key feature when dealing with communication of
these models. The recent EFSA uncertainty guidance document pro-
vides a reporting table for listing and evaluating model uncertainties
[19].
From the 2016 EURL ECVAM workshop, the following graphical
representation and application of the “credibility matrix by Patterson &
Whelan” has been proposed. The matrix (Fig. 4) allows for locating a
speciﬁc model type based on the information available, i.e whether a
model is principled and testable, as well as knowledge of the biology
and the availability of data, which should aid in systematically estab-
lishing model credibility via a process of social epistemology [46]. If a
model falls in the bottom left region (testable and with full knowledge),
conﬁdence in the model is likely high. However, if a model falls in the
top right region of the matrix (not testable and without any knowledge
of the system biology), conﬁdence in the model is likely low due to the
uncertainties associated with it. In other words, regulators are unlikely
to trust model types found in the top right region of the matrix when
making decisions. The question is, to what degree a PBK model would
need to be placed towards the bottom left corner to attain suﬃcient
credibility for regulators. In some sense, testable models do not really
predict, but provide an estimate to compare against available data in a
retrospective fashion.
The proposed framework should lay out the requirements for vali-
dating models with diﬀerent degrees of knowledge and testability (e.g.,
quantitative validation), which could aid in quantifying the uncertainty
currently existing with animal models, and which can help regulators
assess whether models developed through in vitro and in silico meth-
odologies can be equally reliable, or even more so, compared to current
risk assessment approaches. Biological systems, by nature, are complex
networks operating under simple rules that can be described by non-
linear dynamic processes, and which exhibit non-trivial emergent and
self-organizing behavior. As a result, a measured value might represent
a particular, and perhaps unknown, state of a system, which makes its
use, as a comparator for a predicted value, challenging. To handle such
issues, approaches that operate on experience-based validation are re-
quired. Ideally, these, approaches would capture the diversity of ex-
periences to establish generic digital twins, which are couplings of
validated models with their real-world datasets (see [45]).
There is disagreement amongst modellers as to the meaning of the
terms model evaluation, veriﬁcation, and validation; for instance, EMA
has shifted to use of the word “qualiﬁcation”. Regardless of which term
is more appropriate, the analytical purpose is to ensure that the model
is appropriate for the task at hand, and that its predictions are a rea-
sonable representation of reality. Once conﬁrming that the model is a
reasonable representation of reality for the intended purpose, several
analyses may be used to “validate” a model, including sensitivity ana-
lysis, robustness analysis5, assumption justiﬁcation, model argumenta-
tion, structured calibration, predictive performance, proper scoring
rules, and relation to reality. To “verify” a model, the model scope
should be revisited and the model equations and code reviewed. The
following key elements were suggested by the 2016 EURL ECVAM
workshop participants to achieve model credibility [42]:
• Understand the model;
• Understand the data underpinning the model;
• State clearly the assumptions and hypothesis encoded;
• Consider the gap between the model and reality, based on available
observations.
This last item can be a description of what is lacking in the model.
The outcomes of sensitivity analyses can be used to explain some model
deﬁcits. One possible approach, as opposed to the statement in the
introduction regarding developing the simplest model, would be to start
with a more complex model and then remove parameters to which the
predictions are not sensitive. The potential problem with this approach
is that when there are many parameters with large uncertainties, they
may introduce a great deal of variation into the uncertainty analysis.
4.5. Reliability of dose metric predictions (model testing, uncertainty, and
sensitivity)
In 2010, the World Health Organization (WHO) reported the level of
conﬁdence needed to gain credibility in a PBK model intended for risk
assessment (WHO, 2010). The degree of conﬁdence in a PBK model’s
predictions depends upon how well the model has been tested against
real data and whether adequate sensitivity and uncertainty analyses
have been conducted, in order to support the reliability of predictions
(WHO, 2010). In the case of NG-PBK models, the lack of “real data”
(e.g. in vivo human data) that are required to evaluate model predic-
tions for the purpose of validation render such validation nearly im-
possible. However, reporting of adequate sensitivity and uncertainty is
certainly relevant and encouraged. Tables providing guidance in re-
porting results of uncertainty and sensitivity analyses have been
5 Quotation from Saltelli et al 2000 Sensitivity Analysis – What is Sensitivity
Analysis? “For a software engineer, SA could be related to the robustness and
reliability of the software with respect to diﬀerent assumptions “ … “For a
statistician, involved in statistical modelling, SA is mostly known and practice
under the heading of “robustness analysis” [53].
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provided in the WHO 2010 article, as a tool to better document the
evaluation of model predictions (from WHO 2010; [39]). There are
several areas that are considered to present current challenges in ac-
cepting model-informed drug development, which can also provide
insight into necessary acceptance criteria for PBK model-based drug
development. Among those criteria, most noteworthy is that the ade-
quacy of submitted PBK models is to be based on their intended pur-
poses at diﬀerent stages of drug development [42]. That is, determi-
nation of whether a model is ﬁt-for-purpose and the need to identify
and transparently communicate the knowledge gaps. EMA and US FDA
published a draft document in 2016 as guidance on the qualiﬁcation
and reporting of physiologically based pharmacokinetic (PBPK) mod-
elling and simulations [20,60]. The aim of this guideline is to describe
the expected content that should be included in PBK modelling and
simulation reports during regulatory submission, including applications
for authorization of medicinal products, pediatric investigation plans,
and clinical trial applications. This also includes the documentation
needed to support the qualiﬁcation of a PBK platform for an intended
use, such as results of sensitivity and uncertainty analyses.
4.6. Population characteristics and virtual population libraries
This chapter reports information on population characteristics as
virtual population libraries for the in silico medicine ﬁeld. However we
believe that this information could be also relevant for chemical risk
assessment. Eﬀorts undertaken to better capture the heterogeneity in
the human species can certainly be applied to environmental chemical
risks, as diﬀerent population cohorts may be more at risk to speciﬁc
chemical exposures than are other cohorts. Important aspects of human
heterogeneity include inter-individual variations in lifestyle, health
status (immunosuppressed, disease patient) genetic polymorphism
(gene expression), physiology (uptake rate), biochemistry and
molecular biology [38], all with respect to age. These factors will in-
teract and inﬂuence the chemical ADME and biokinetic behaviors and
toxicodynamics within the body. Parameters in a PBK model have a
direct biological correspondence, providing a useful framework for
determining the impact of observed variations in physiological and
biochemical factors on the population variability in the achieved target
of a particular chemical [16,48,38]. In addition, integration of genetic
information from –omics studies will enhance predictions for precise
and personalized medicine. Applications for predicting the kinetics of
substances within speciﬁc populations, such as in the ﬁeld of pediatrics,
have been increasing in their development and use [31]. In the phar-
maceutical ﬁeld, population-speciﬁc PBK models can simulate un-
testable clinical outcomes, allowing for evaluating the eﬀects of in-
trinsic (e.g., organ dysfunction, age, genetics, etc.) and extrinsic (e.g.,
drug-drug interactions) factors, alone or in combination, on drug target
concentrations.
5. Next steps and future perspectives
With an increasing demand for application of alternative methods
within the risk assessment framework, the need for the development of
higher throughput NG-PBK models has also increased. A guidance
document for GMP for PBK modelling could also be extended to other
types of in silico biokinetic models, such as in vitro mass balance models
[3,73]. Existing guidance documents [68,57], and those documents of
EFSA [18], and CEN [12], that are less PBK-speciﬁc, require updating
with respect to the current trends, due to the continuous evolution in
science and risk assessment. The recent FDA [60] and EMA [20]
guidelines are the ﬁrst that open up the possibility to submit non-an-
imal PBK model results for drug dossier submission and provide ex-
cellent examples that other agencies could follow. At the same time, the
OECD is working on a guidance document for the characterization,
Fig. 4. Credibility matrix showing comparative loci for a model based on traditional in vivo data-based approaches and for a model based on an alternative approach
(i.e., in vitro, in silico methods, and/or micro-scale systems). The rationale for the locations of the model types, indicated by stars and letters, are given in the side-bar
legend. For example, in silico models placed at the top right, might consist of a simple model ‘a’ based on a limited set of data, for instance in a QSAR. This leads to a
more sophisticated, but still heuristic, model ‘b’ based on the understanding gained from model ‘a’. The predictions from models ‘a’ and ‘b’ are used to design in vitro
tests that enable the development of model ‘c’, which can be validated using the rational-empirical approach, thus enhancing its credibility. Finally, this leads to the
development of clinical studies and model ‘d’, supported by its predecessors and quantitatively validated or conﬁrmed using clinical data. This places model ‘d’ in the
bottom left corner, as a model whose predictions stakeholders, including regulators, practitioners, and patients, will likely use to make decisions (adapted from [42],
proposed by [46]).
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validation, and reporting of physiologically based models for regulatory
applications that should be ready in 2019, and which attempts to set
principles for NG-PBK model validation.
However, the challenge remains in making appropriate use of in
vitro data and/or in silico predictions when 1) building these models; 2)
interpreting model outputs and integrating the outputs with other
sources of information for risk assessment purposes; and 3) attempting
to gain model credibility by underlining all uncertainties and assump-
tions when in vivo human data are unavailable for proper model eva-
luation. The uncertainty and variability associated with PBK models,
and the proposed GMP [32], should be further developed and should
include guidance for PBK models built using in vitro and in silico
methodologies to estimate ADME properties. The use of a matrix in the
new risk assessment paradigm, to underline and quantify the un-
certainty associated with NG-PBK models, compared to models based
on in vivo animal data, would be desirable.
Several standardised decision trees could be developed to guide
modellers in their construction of a PBK model in the absence of in vivo
data for calibration, and to guide risk assessors in application and in-
terpretation of PBK models. For instance, PBK-predicted internal dose
metrics vs. in vitro PoD from toxicity testing could be taken into ac-
count, along with in vitro results linking to in vivo adverse outcomes for
a tiered assessment, perhaps through application of the traditional and
internal threshold of toxicological concern approach [29,69]. With the
need for several international working groups to further develop such
documentation, communication is required among these groups to en-
sure compatibility of in vitro kinetic and dynamic methods with PBK
models, in addition to communication with regulators to ﬁt the total
risk-assessment framework. It should be noted that for such commu-
nication to be achieved, funding would be necessary.
There remains a need to create a community to address issues with
human ADME/TK and NG-PBK models, such as the development of
criteria for model construction and model evaluation. A group of sci-
entists across the academic, industrial, and governmental landscapes
should be available and willing to establish a peer review system for
PBK models. Criteria should exist to select those individuals that will
review the models, and templates and check lists should be provided to
assist in the review process. A public repository is needed for PBK
models that have been built and/or peer reviewed, and once this re-
pository is developed, relevant documentation can be introduced from
an independent peer review to support model credibility. Such a re-
pository is in line with the work reported in Lu et al., [36] and will
allow for the curation of more case studies and the creation of libraries
of ad hoc PBK models that could be used for training purposes. Ad-
ditionally, this repository will facilitate risk assessment approaches
applying PBK models and IVIVE, and communicate to decision makers
more eﬃciently the current state of science regarding the use of animal-
free models in regulatory applications. Perspectives from the various
industrial stakeholders (e.g. pharmaceutical, food safety, agricultural,
and personal care product industries) also need to be communicated, to
provide greater insight of current practice and understanding of future
needs of these sectors, to enable promotion of best practices.
Application of NG-PBK models, in the context of exposure in speciﬁc
population of patients, would be extremely valuable in the generation
of virtual population/patient libraries. These libraries would enable
clinical trials to entail populations with a greater number of “virtual”
individuals, which might not otherwise be possible to conduct with a
limited number of real persons/patients. Additionally, these libraries
would introduce populations more rarely encountered, such as those
possessing enzyme polymorphisms that exert a greater inﬂuence on
drug-drug interactions or those with rare genetic diseases or health
abnormalities. Such libraries would also prove useful in chemical risk
assessment when evaluating interindividual variability in relation to
chemical exposures and toxicological outcomes.
Finally, it is recommended that a means for training new modellers
and risk assessors be established. Such training, which can be provided
with speciﬁc courses or as a continuing education course at scientiﬁc
conferences, will focus on PBK model development, evaluation, and
application. Though several challenges still remain, the suggestions and
steps presented in this work provide a path towards gaining acceptance
of NG-PBK models in regulatory practices.
In summary, to facilitate the development and use of NG-PBK
models, which do not rely on animal in vivo data, and their acceptance
in the regulatory domain, the following are recommended:
i) development of more transparent, accessible, and user-friendly
software platforms that facilitate development and application of
PBK models by a community of users, and which allow speciﬁc
populations to be modelled or population variability to be eval-
uated;
ii) development of resources to inform new developments in in silico
and in vitro approaches that may be used to provide data for model
development;
iii) development and reﬁnement of existing web applications and PBK
model platforms that have the ability to conduct QIVIVE and re-
verse dosimetry in an automated manner;
iv) knowledge sharing initiatives that allow members of the regulatory
community, such as risk assessors and risk managers, to become
familiar with relevant PBK model information, while model devel-
opers gain a better understanding of regulatory needs;
v) GMPs and harmonised guidelines for reporting the steps taken
during model development, evaluation, and application, with re-
spect to NG- PBK models. This would include the use of a clear and
common terminologies.
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